Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia.
El tratamiento del paciente oncológico es complejo debido a que la naturaleza de la patología requiere un manejo sistémico. Las distintas terapias que buscan restablecer la salud de los pacientes, o al menos procurarles calidad de vida, deben modificarse constantemente, porque sus efectos adversos a menudo provocan que los pacientes interrumpan su tratamiento o lo abandonen por completo. Tal es el caso de la náusea y el vómito inducidos por radioterapia y quimioterapia, que provocan mayor malestar a los pacientes y que, desde hace más de dos décadas, han tratado de ser controlados con antieméticos cada vez más efectivos. Desde hace tiempo, diversas instituciones oncológicas internacionales han publicado guías para homologar los criterios de... Ver más
Guardado en:
2256-2877
2256-2915
2
2013-07-01
32
40
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Francisco Javier Ochoa Carrillo - 2013
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
| id |
aff43abcb1dc20b5dd75504aeffbec64 |
|---|---|
| record_format |
ojs |
| spelling |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. Herrsted J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101(3):143-50. Roila F, Del Favero A, Gralla RJ, Tonato M. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998;9(8):811-9. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2005;13(2):117-21. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533-8. NCCN clinical practice guidelines in oncology. Antiemesis. 2012. Available in: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. ASCO guidelines 2011, MASCC y ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5);v232-43. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-98. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-8. Valle-Solís AE, Cervantes-Sánchez G, Franco-González EE, García G, Hernández-Chávez GA, López-Hernández M, et al. Guías de manejo de antieméticos en oncología, hematología y radioterapia. GAMO. 2011;10 (supl 4):1-20. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment for chemotherapy-induced nausea and vomiting: past, present, and future recommendations. The Oncologist. 2007;12(9):1143-50. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-94. de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-101. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin. 1989;39(2):89-104. Maule WF. Nausea and vomiting. Chapter 84. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990. Chambers P, Daniels S. Antiemetic guidelines for adult patients receiving chemotherapy and radiotherapy. University College Hospital NHS Foundation Trust; 2012. p. 1-15. Rodríguez R. Náusea crónica y vómito en el paciente con cáncer. Disponible en: http://www.paho.org/spanish/ad/dpc/nc/palliative-care-08.pdf. Chung SK, Ahn MJ, Yoo JY, Choi M, Hyang N, Woo SR, et al. Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute setting. Int J Evid Based Healthc 2011;9(1):32-8. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17(9):2971-94. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30-8. Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. Francisco Javier Ochoa Carrillo - 2013 Durand JP, Madelaine I, Scotté F. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting]. Bull Cancer. 2009;96(10):951-60. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006;2(5):591-602. Español Menéndez-Leal A, Quijano C, Menéndez-Rivera A. Is gabapentin effective for preventing delayed NV after moderately and highly emetogenic CT. ASCO 2006 Abstr 18575. Text http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/publishedVersion http://purl.org/redcol/resource_type/ARTREF http://purl.org/coar/resource_type/c_6501 info:eu-repo/semantics/article Razzavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol. 1993;11(7):1384-90. Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012;20(3):601-6. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, RiveraMárquez H, Villasis-Keever MA, Del Ángel VW, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res. 2008;39(6):601-6. NCCN guidelines version 3.2011. Antiemesis. Available in: http://www.nccn.org/index.asp. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Single-dose fosaprepitant for the prevention of chemotherapyinduced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011;29(11):1495-501. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-8. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-9. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol. 1998;16(9):2937-42. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of neurokinin1 receptor antagonist aprepipant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17-24. Likun Z, Xiang J, Yi B, Xin D, Liu-Tao Z. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. The Oncologist. 2011;16(2):207-16. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52(2):242-7. Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2010;(9):CD007786. https://creativecommons.org/licenses/by-nc-sa/4.0 Publication https://revista.acho.info/index.php/acho/article/view/342 Rodríguez, Ivo vómito emesis efectos adversos radioterapia quimioterapia Vargas, Carlos Torres, María Alejandra Suazo Casanova, Juan Fernando Miguel Rojas Montero, José Federico Ponce de León Herrera, Andrea antineoplásicos Menéndez Leal, Álvaro Manneh, Raimundo Mahave, Mauricio López Aguilar, Enrique León, María Isabel Duarte, Óscar Daniel Cervantes Sánchez, María Guadalupe Caponero, Ricardo Ochoa Carrillo, Francisco Javier El tratamiento del paciente oncológico es complejo debido a que la naturaleza de la patología requiere un manejo sistémico. Las distintas terapias que buscan restablecer la salud de los pacientes, o al menos procurarles calidad de vida, deben modificarse constantemente, porque sus efectos adversos a menudo provocan que los pacientes interrumpan su tratamiento o lo abandonen por completo. Tal es el caso de la náusea y el vómito inducidos por radioterapia y quimioterapia, que provocan mayor malestar a los pacientes y que, desde hace más de dos décadas, han tratado de ser controlados con antieméticos cada vez más efectivos. Desde hace tiempo, diversas instituciones oncológicas internacionales han publicado guías para homologar los criterios del manejo de la náusea y vómito inducidos por quimioterapia; sin embargo, hasta el momento, se ha carecido de guías y lineamientos específicos adaptados para Latinoamérica, región donde existen circunstancias particulares referentes a la disposición de fármacos y al acceso a recursos. Ante ese panorama, un grupo de especialistas oncólogos, hematólogos y oncólogos pediátricos de Latinoamérica se reunió con el propósito de consensuar el manejo general y las recomendaciones específicas sobre el uso de los fármacos antieméticos, solos o en combinación, y conformar las guías del manejo de la emesis, de acuerdo con las particularidades del contexto latinoamericano. Los expertos contestaron un cuestionario Delphi que contenía los conceptos fundamentales del tratamiento antiemético. Los calificaron mediante parámetros de acuerdo y desacuerdo. Posteriormente, se reunieron para llegar a un consenso en los que requerían discusión y revisaron los reportes más relevantes de las publicaciones internacionales (incluidas las guías de MASCC, NCCN y ASCO). Finalmente, se redactaron las guías latinoamericanas para el control de la emesis. náusea antieméticos Revista Colombiana de Hematología y Oncología 2 application/pdf Artículo de revista Núm. 2 , Año 2013 : Julio Asociación Colombiana de Hematología y Oncología (ACHO) 2 antineoplastic antiemetics nausea vomiting emesis adverse effects Journal article Latin-american guidelines for the management of emesis in oncology, haemato-oncology, and radiotherapy. The treatment for the oncological patient is complex because the pathology in itself requires a systemic management. The different therapies –which search for restoring the health of the patients, or at least improving their quality of life– constantly must be modified because their adverse effects usually make the patients to interrupt the treatment or abandon it altogether. Such is the case of nausea and vomiting induced by radiotherapy and chemotherapy, which cause troublesome ailments to the patients and that have been treated with more effective antiemetics for over two decades. Long time ago, several international oncological institutions have published guidelines to homogenize the management criteria of the nausea and vomiting induced by chemotherapy. Nevertheless, there has been a lack of specific and adaptive guidelines for LatinAmerica, region where there are particular circumstances related to drugs availability and access to resources. Taking all this into account, a group of oncologists, haematologists, and paediatric oncologists from Latin-America gathered with the purpose of agreeing about the general management and specific recommendations of the antiemetic drugs administration alone or in combination; as well as to establish the management of emesis guidelines according to the Latin-American context. The experts answered a Delphi questionnaire which contained the basic concepts of the antiemetic treatment. They graded them with the criteria agree and disagree. Later on, they assembled again to discuss the controversial concepts, reviewed the most outstanding literature reports (including the MASCC, NCCN, and ASCO guidelines), and finally, they draw up the Latin-American guides for the control of emesis. radiotherapy chemotherapy 2256-2915 2256-2877 2013-07-01T00:00:00Z 32 40 https://revista.acho.info/index.php/acho/article/download/342/304 2013-07-01 2013-07-01T00:00:00Z 10.51643/22562915.342 https://doi.org/10.51643/22562915.342 |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| spellingShingle |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. Rodríguez, Ivo Vargas, Carlos Torres, María Alejandra Suazo Casanova, Juan Fernando Miguel Rojas Montero, José Federico Ponce de León Herrera, Andrea Menéndez Leal, Álvaro Manneh, Raimundo Mahave, Mauricio López Aguilar, Enrique León, María Isabel Duarte, Óscar Daniel Cervantes Sánchez, María Guadalupe Caponero, Ricardo Ochoa Carrillo, Francisco Javier vómito emesis efectos adversos radioterapia quimioterapia antineoplásicos náusea antieméticos antineoplastic antiemetics nausea vomiting emesis adverse effects radiotherapy chemotherapy |
| title_short |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| title_full |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| title_fullStr |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| title_full_unstemmed |
Guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| title_sort |
guías latinoamericanas para el manejo de la emesis en oncología, hematooncología y radioterapia. |
| title_eng |
Latin-american guidelines for the management of emesis in oncology, haemato-oncology, and radiotherapy. |
| description |
El tratamiento del paciente oncológico es complejo debido a que la naturaleza de la patología requiere un manejo sistémico. Las distintas terapias que buscan restablecer la salud de los pacientes, o al menos procurarles calidad de vida, deben modificarse constantemente, porque sus efectos adversos a menudo provocan que los pacientes interrumpan su tratamiento o lo abandonen por completo. Tal es el caso de la náusea y el vómito inducidos por radioterapia y quimioterapia, que provocan mayor malestar a los pacientes y que, desde hace más de dos décadas, han tratado de ser controlados con antieméticos cada vez más efectivos. Desde hace tiempo, diversas instituciones oncológicas internacionales han publicado guías para homologar los criterios del manejo de la náusea y vómito inducidos por quimioterapia; sin embargo, hasta el momento, se ha carecido de guías y lineamientos específicos adaptados para Latinoamérica, región donde existen circunstancias particulares referentes a la disposición de fármacos y al acceso a recursos. Ante ese panorama, un grupo de especialistas oncólogos, hematólogos y oncólogos pediátricos de Latinoamérica se reunió con el propósito de consensuar el manejo general y las recomendaciones específicas sobre el uso de los fármacos antieméticos, solos o en combinación, y conformar las guías del manejo de la emesis, de acuerdo con las particularidades del contexto latinoamericano. Los expertos contestaron un cuestionario Delphi que contenía los conceptos fundamentales del tratamiento antiemético. Los calificaron mediante parámetros de acuerdo y desacuerdo. Posteriormente, se reunieron para llegar a un consenso en los que requerían discusión y revisaron los reportes más relevantes de las publicaciones internacionales (incluidas las guías de MASCC, NCCN y ASCO). Finalmente, se redactaron las guías latinoamericanas para el control de la emesis.
|
| description_eng |
The treatment for the oncological patient is complex because the pathology in itself requires a systemic management. The different therapies –which search for restoring the health of the patients, or at least improving their quality of life– constantly must be modified because their adverse effects usually make the patients to interrupt the treatment or abandon it altogether. Such is the case of nausea and vomiting induced by radiotherapy and chemotherapy, which cause troublesome ailments to the patients and that have been treated with more effective antiemetics for over two decades. Long time ago, several international oncological institutions have published guidelines to homogenize the management criteria of the nausea and vomiting induced by chemotherapy. Nevertheless, there has been a lack of specific and adaptive guidelines for LatinAmerica, region where there are particular circumstances related to drugs availability and access to resources. Taking all this into account, a group of oncologists, haematologists, and paediatric oncologists from Latin-America gathered with the purpose of agreeing about the general management and specific recommendations of the antiemetic drugs administration alone or in combination; as well as to establish the management of emesis guidelines according to the Latin-American context. The experts answered a Delphi questionnaire which contained the basic concepts of the antiemetic treatment. They graded them with the criteria agree and disagree. Later on, they assembled again to discuss the controversial concepts, reviewed the most outstanding literature reports (including the MASCC, NCCN, and ASCO guidelines), and finally, they draw up the Latin-American guides for the control of emesis.
|
| author |
Rodríguez, Ivo Vargas, Carlos Torres, María Alejandra Suazo Casanova, Juan Fernando Miguel Rojas Montero, José Federico Ponce de León Herrera, Andrea Menéndez Leal, Álvaro Manneh, Raimundo Mahave, Mauricio López Aguilar, Enrique León, María Isabel Duarte, Óscar Daniel Cervantes Sánchez, María Guadalupe Caponero, Ricardo Ochoa Carrillo, Francisco Javier |
| author_facet |
Rodríguez, Ivo Vargas, Carlos Torres, María Alejandra Suazo Casanova, Juan Fernando Miguel Rojas Montero, José Federico Ponce de León Herrera, Andrea Menéndez Leal, Álvaro Manneh, Raimundo Mahave, Mauricio López Aguilar, Enrique León, María Isabel Duarte, Óscar Daniel Cervantes Sánchez, María Guadalupe Caponero, Ricardo Ochoa Carrillo, Francisco Javier |
| topicspa_str_mv |
vómito emesis efectos adversos radioterapia quimioterapia antineoplásicos náusea antieméticos |
| topic |
vómito emesis efectos adversos radioterapia quimioterapia antineoplásicos náusea antieméticos antineoplastic antiemetics nausea vomiting emesis adverse effects radiotherapy chemotherapy |
| topic_facet |
vómito emesis efectos adversos radioterapia quimioterapia antineoplásicos náusea antieméticos antineoplastic antiemetics nausea vomiting emesis adverse effects radiotherapy chemotherapy |
| citationvolume |
2 |
| citationissue |
2 |
| citationedition |
Núm. 2 , Año 2013 : Julio |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/342 |
| language |
Español |
| format |
Article |
| rights |
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. Francisco Javier Ochoa Carrillo - 2013 http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0 |
| references |
Herrsted J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101(3):143-50. Roila F, Del Favero A, Gralla RJ, Tonato M. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998;9(8):811-9. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2005;13(2):117-21. Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533-8. NCCN clinical practice guidelines in oncology. Antiemesis. 2012. Available in: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. ASCO guidelines 2011, MASCC y ESMO clinical practice guidelines. Ann Oncol. 2010;21(Suppl 5);v232-43. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-98. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-8. Valle-Solís AE, Cervantes-Sánchez G, Franco-González EE, García G, Hernández-Chávez GA, López-Hernández M, et al. Guías de manejo de antieméticos en oncología, hematología y radioterapia. GAMO. 2011;10 (supl 4):1-20. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment for chemotherapy-induced nausea and vomiting: past, present, and future recommendations. The Oncologist. 2007;12(9):1143-50. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-94. de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-101. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin. 1989;39(2):89-104. Maule WF. Nausea and vomiting. Chapter 84. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990. Chambers P, Daniels S. Antiemetic guidelines for adult patients receiving chemotherapy and radiotherapy. University College Hospital NHS Foundation Trust; 2012. p. 1-15. Rodríguez R. Náusea crónica y vómito en el paciente con cáncer. Disponible en: http://www.paho.org/spanish/ad/dpc/nc/palliative-care-08.pdf. Chung SK, Ahn MJ, Yoo JY, Choi M, Hyang N, Woo SR, et al. Implementation of best practice for chemotherapy-induced nausea and vomiting in an acute setting. Int J Evid Based Healthc 2011;9(1):32-8. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17(9):2971-94. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30-8. Durand JP, Madelaine I, Scotté F. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting]. Bull Cancer. 2009;96(10):951-60. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006;2(5):591-602. Menéndez-Leal A, Quijano C, Menéndez-Rivera A. Is gabapentin effective for preventing delayed NV after moderately and highly emetogenic CT. ASCO 2006 Abstr 18575. Razzavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol. 1993;11(7):1384-90. Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012;20(3):601-6. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, RiveraMárquez H, Villasis-Keever MA, Del Ángel VW, et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res. 2008;39(6):601-6. NCCN guidelines version 3.2011. Antiemesis. Available in: http://www.nccn.org/index.asp. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Single-dose fosaprepitant for the prevention of chemotherapyinduced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011;29(11):1495-501. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-8. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-9. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol. 1998;16(9):2937-42. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of neurokinin1 receptor antagonist aprepipant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17-24. Likun Z, Xiang J, Yi B, Xin D, Liu-Tao Z. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. The Oncologist. 2011;16(2):207-16. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52(2):242-7. Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2010;(9):CD007786. |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2013-07-01 |
| date_accessioned |
2013-07-01T00:00:00Z |
| date_available |
2013-07-01T00:00:00Z |
| url |
https://revista.acho.info/index.php/acho/article/view/342 |
| url_doi |
https://doi.org/10.51643/22562915.342 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.342 |
| citationstartpage |
32 |
| citationendpage |
40 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/342/304 |
| _version_ |
1797159761425203200 |